tirzepatide off label is a novel medication that the FDA has approved for treating type 2 diabetes mellitus. Due to its potent weight loss properties, Tirzepatide can be used off-label for treating obesity. The Weight Loss

Studies show most patients regain part of the lost weight and see A1C drift upward within 3-6 months

Reducing the severity and duration of colds and infections

Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: systematic review and meta-analysis

Through molecular docking and machine learning model screening, new molecules with promising anticancer properties have been identified from natural compounds and validated for activity in cellular and animal models (258)

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and families

Efficacy of oral versus intravenous N-acetyl-cysteine in acetaminophen overdose: results of an open-label, clinical trial